Tilray Brands no longer hinges its future on U.S. marijuana legalization. The company’s fiscal first-quarter 2027 numbers reveal a dramatic pivot, with beverage revenue nearly doubling year over year while cannabis sales lag far behind.
For years, cannabis investors pinned their hopes on Washington rescheduling pot. That shift finally happened, easing research restrictions, but it falls far short of full legalization. Meanwhile, Tilray executives have spent that time reshaping the business into something broader and less dependent on American drug policy.
Founded as a pure-play marijuana stock, Tilray went public when cannabis companies dominated market headlines. Financial underperformance across the sector, driven by slow legalization and fierce competition from both licensed and illicit sellers, sent those stocks tumbling. Tilray responded with acquisitions and strategic expansion beyond pot.
The latest quarterly results show how far that transformation has progressed. Beverages, primarily beer, generated $101.5 million in revenue, an 82% jump attributed to a major acquisition. Cannabis contributed just $56.1 million. Tilray has effectively become a beverage company with a marijuana division attached.
Geographic diversification tells a similar story. Sales across Europe, the Middle East, and Africa climbed 71%, buoyed by the same acquisition. International markets now drive growth while U.S. marijuana reform remains a secondary concern.
Tilray still lost money in the first quarter. Profitability remains elusive. But management’s stated goal, becoming a global consumer packaged goods company spanning beverages, cannabis, and wellness, continues taking shape.
The next test becomes whether sustained beverage growth and international expansion convert Tilray’s diversified footprint into consistent earnings. Investors watching for U.S. rescheduling headlines may miss the more consequential story unfolding across the Atlantic.
